Русский / English
Enter the query
23.11.2016
PETROVAX PHARM AND BOEHRINGER INGELHEIM TO LOCALISE PRODUCTION OF CARDIOVASCULAR MEDICATIONS IN RUSSIA

NPO Petrovax Pharm and Boehringer Ingelheim continue their work to localise full-cycle production of biotechnological medicines to treat infarctions and cerebrovascular accidents.
The project aiming to produce innovative thrombolytic medicines in Russia was launched in June, when NPO Petrovax Pharm and Boehringer Ingelheim signed a joint cooperation agreement in the Chamber of Commerce and Industry of the Russian Federation during a meeting discussing the development of high-tech medical care for the prevention of cardiovascular diseases in Russia. The agreement effected as part of Pharma 2020, Russia’s federal targeted programme for pharmaceutical industry development, will be another step towards making life essential medicines more affordable and help to save lives of tens of thousands of patients.
By the end of 2019, NPO Petrovax Pharm and Boehringer Ingelheim intend to complete the transfer of technologies and to launch full-cycle production of innovative thrombolytic medicines at Petrovax Pharm’s production facility in the Moscow Region.
For Boehringer Ingelheim, this is the first localisation project of its kind: Petrovax Pharm will be the world’s second site to manufacture Boehringer Ingelheim’s innovative thrombolytic medications. The facility’s capacity will be enough to fully meet the need for these drugs in Russia.